Efficacy and Safety of Dupilumab for COPD with Type 2 Inflammation Indicated by Elevated Eosinophils

Shweta Bhatt; Henrik Watz; Klaus F. Rabe; NA Hanania; Claus Vogelmeier; Joby Cole; Mona Bafadhel; Stephanie A. Christenson; Alberto Papi; Dave Singh; Elizabeth Laws; Xin Lu; Dirk Bauer; Eric Mortensen; Jennifer Maloney; Ashish Bansal; L Robinson; R Abdulai

doi:10.1055/s-0044-1781407

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Introduction: Dupilumab (DPL), a fully human mAb, blocks the shared receptor component for IL-4 and IL-13, key/central drivers of Type 2 (T2) inflammation. The objective is to determine efficacy/safety in patients with moderate-to-severe COPD with T2 inflammation.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bhatt et al. (2024) studied this question.

synapsesocial.com/papers/68e76835b6db6435876ddf8e https://doi.org/10.1055/s-0044-1781407

View at Publisher

Ask AI

Bookmark

Share

Efficacy and Safety of Dupilumab for COPD with Type 2 Inflammation Indicated by Elevated Eosinophils

Ask about this paper

Abstract

Discussion

Cite This Study

Efficacy and Safety of Dupilumab for COPD with Type 2 Inflammation Indicated by Elevated Eosinophils

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading